Transgenic introduction of androgen receptor into estrogen-receptor–, progesterone-receptor–, and androgen-receptor–negative breast cancer cells renders them responsive to hormonal manipulation - 19/08/11
, SuEllen Pommier, Ph.D.
Corresponding author. Tel.: +1-503-494-5550; fax: +1-503-494-7573Abstract |
Background |
Estrogen-receptor (ER)–, progesterone-receptor (PR)–, and androgen-receptor (AR)–negative breast cancer cells are unaffected by treatment with dehydroepiandrosterone-sulfate (DHEAS) and an aromatase inhibitor (AI). We hypothesized that cell growth would be inhibited with DHEAS/AI treatment after successful transfection of an AR expression vector.
Methods |
ER/PR/AR–negative breast cancer cells were transfected with an AR expression vector and treated with DHEAS/AI for 2 days. Growth inhibition of these cells was compared with that of transfected cells treated with only AI or with nontransfected cells treated with DHEAS/AI. Mann-Whitney U test was used to determine statistical significance.
Results |
Cell death rates of 53.5% (P = .001) and 40.1% (P = .006) were seen in transfected cells treated with DHEAS/AI compared with controls for days 1 and 2, respectively. Nontransfected cells were unaffected by treatment.
Comments |
ER/PR/AR–negative cells transfected with AR were killed by DHEAS/AI treatment, providing evidence that AR is responsible for this effect. This provides the first AR-targeted hormonal therapy for ER breast cancer.
Le texte complet de cet article est disponible en PDF.Keywords : Androgen receptor, Aromatase inhibitor, Breast cancer, Dehydroepiandrosterone-sulfate
Plan
Vol 191 - N° 5
P. 576-580 - mai 2006 Retour au numéro
Article précédent
- Dr. Oswald Meredith Jones, a talented and gallant Welshman
- James C. Donald, Stuart P. Kenning
- Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma
- Sam M. Wiseman, Hamid Masoudi, Paddy Niblock, Dmitry Turbin, Ashish Rajput, John Hay, Douglas Filipenko, David Huntsman, Blake Gilks
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?